FDA Accepts Application for a New HS Treatment

Bimekizumab is currently approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Related Keywords

United States , ,Drug Administration ,European Union ,Biologics License Application ,Psoriasis ,Psoriatic Arthritis ,Rthropathic Psoriasis ,Psoriatic Arthropathy ,Sa ,Phototherapy ,Light Therapy ,Plaque Psoriasis ,Hidradenitis Suppurativa ,Skin And Soft Tissue Infection ,Ankylosing Spondylitis ,Heumatoid Spondylitis ,Heumatoid Arthritis Of The Spine ,Echterew Amp 039s Disease ,Echterew Syndrome ,Marie Strumpell Disease ,Arie Struempell Disease ,Spondyloarthritis ,Spondylosis ,